28 July 2017
Few studies have evaluated the prognostic value of total tumor volume (TTV), which reflects both the primary tumor volume and nodal tumor volume, in NPC. Furthermore, the relationship between TTV and survival remains unknown. The purpose of this study was to evaluate the prognostic value of TTV in patients with NPC treated with intensity-modulated radiation therapy (IMRT).
TTV was retrospectively assessed in 455 patients with newly diagnosed, non-metastatic NPC. All patients were treated using IMRT; 91.1% (288/316) of patients with stage III-IVb also received cisplatin-based chemotherapy. Receiver operating characteristic (ROC) curves were used to identify the optimal TTV cut-off point and examine the prognostic value of combined TTV with current clinical stage.
Mean TTV was 11.1 cm 3 (range, 0.3–27.9 cm 3) in stage I, 22.5 cm 3 (1.3–92.4 cm 3) in stage II, 40.6 cm 3 in stage III (3.2–129.2 cm 3), and 77.5 cm 3 in stage IVa-b (7.1–284.1 cm 3). For all patients, the 4-year estimated FFS, OS, DMFS, and LRRFS rates for patients with a TTV ≤ 28 vs. > 28 cm 3 were 93 vs. 71.4% ( P < 0.001), 95.1 vs. 75.4% ( P < 0.001), 94.5 vs. 79.4% ( P < 0.001), and 96.2 vs. 88% ( P = 0.001). TTV was an independent prognostic factor for FFS, OS, DMFS and LRRFS in all patients. In stage III-IVb, 4-year estimated FFS, OS, DMFS, and LRRFS for a TTV ≤28 vs. >28 cm 3 were 88.9 vs. 70.5% ( P = 0.001), 96.2 vs. 72.7% ( P < 0.001), 91.2 vs. 78.3% ( P = 0.008), and 93.8 vs. 87.6% ( P = 0.063). TTV was an independent prognostic factor for FFS, OS and DMFS in stage III-IVb. Receiver operating characteristic (ROC) curve analysis curves revealed adding TTV to clinical stage had superior prognostic value for treatment failure compared to clinical stage alone ( P = 0.016).